Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Genenta Science S.P.A. ADR (GNTA)

Genenta Science S.P.A. ADR (GNTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies,...

PG : 165.08 (-0.01%)
AGRX : 1.5100 (unch)
NMTR : 0.0722 (-42.97%)
GNTA : 5.30 (-2.75%)
AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets...

GNTA : 5.30 (-2.75%)
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the...

GNTA : 5.30 (-2.75%)
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

Extensive experience in business development with AstraZeneca and GSK...

GNTA : 5.30 (-2.75%)
Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the...

GNTA : 5.30 (-2.75%)
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

No dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial ...

GNTA : 5.30 (-2.75%)
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Initial evidence of potential to modulate tumor microenvironment...

GNTA : 5.30 (-2.75%)
Genenta Announces Nomination of Mark A. Sirgo as Chair

35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK,...

GNTA : 5.30 (-2.75%)
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

*** David Reardon, Luigi Naldini, Brad Loncar ***...

GNTA : 5.30 (-2.75%)
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Data to be presented at the 2022 annual meeting of American Association for Cancer Research...

GNTA : 5.30 (-2.75%)

Barchart Exclusives

Is This High-Yield Dividend Stock a Buy After Earnings?
This pharmaceutical giant's Q3 numbers came in ahead of Street estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar